Patents Assigned to Hangzhou Highlightll Pharmaceutical Co., Ltd.
  • Jak1 selective inhibitors and uses thereof
    Patent number: RE49834
    Abstract: The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: February 13, 2024
    Assignee: Hangzhou Highlightll Pharmaceutical Co., Ltd.
    Inventor: Congxin Liang